Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:KYMR NASDAQ:PTGX NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$86.99-2.1%$77.12$47.86▼$107.37$4.93B0.31577,642 shs500,598 shsKYMRKymera Therapeutics$59.83-1.0%$48.83$19.44▼$63.96$4.32B2.26864,750 shs698,387 shsPTGXProtagonist Therapeutics$77.50+2.3%$62.55$33.31▼$93.25$4.71B2.21.69 million shs1.24 million shsSNDXSyndax Pharmaceuticals$14.30-5.0%$15.52$8.58▼$22.50$1.30B0.682.18 million shs4.38 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx-3.81%+0.52%+14.87%+31.45%-4.46%KYMRKymera Therapeutics-3.86%+6.03%+23.94%+30.92%+23.34%PTGXProtagonist Therapeutics-2.51%+12.96%+29.25%+36.50%+61.16%SNDXSyndax Pharmaceuticals+0.07%-7.10%+0.07%+59.09%-24.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$86.99-2.1%$77.12$47.86▼$107.37$4.93B0.31577,642 shs500,598 shsKYMRKymera Therapeutics$59.83-1.0%$48.83$19.44▼$63.96$4.32B2.26864,750 shs698,387 shsPTGXProtagonist Therapeutics$77.50+2.3%$62.55$33.31▼$93.25$4.71B2.21.69 million shs1.24 million shsSNDXSyndax Pharmaceuticals$14.30-5.0%$15.52$8.58▼$22.50$1.30B0.682.18 million shs4.38 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx-3.81%+0.52%+14.87%+31.45%-4.46%KYMRKymera Therapeutics-3.86%+6.03%+23.94%+30.92%+23.34%PTGXProtagonist Therapeutics-2.51%+12.96%+29.25%+36.50%+61.16%SNDXSyndax Pharmaceuticals+0.07%-7.10%+0.07%+59.09%-24.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.86Moderate Buy$113.0830.00% UpsideKYMRKymera Therapeutics 2.95Moderate Buy$62.744.86% UpsidePTGXProtagonist Therapeutics 2.83Moderate Buy$74.00-4.52% DownsideSNDXSyndax Pharmaceuticals 2.91Moderate Buy$38.00165.73% UpsideCurrent Analyst Ratings BreakdownLatest SNDX, ACLX, PTGX, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/17/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $96.0010/17/2025KYMRKymera TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $80.0010/16/2025ACLXArcellxStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$129.0010/16/2025SNDXSyndax PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.0010/15/2025SNDXSyndax PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/13/2025PTGXProtagonist TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/13/2025PTGXProtagonist TherapeuticsJohnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$112.0010/9/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$88.0010/9/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$88.0010/8/2025ACLXArcellxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025KYMRKymera TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M44.70N/AN/A$8.41 per share10.34KYMRKymera Therapeutics$47.07M90.88N/AN/A$12.90 per share4.64PTGXProtagonist Therapeutics$434.43M11.10$4.62 per share16.76$11.33 per share6.84SNDXSyndax Pharmaceuticals$23.68M52.02N/AN/A$3.38 per share4.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$3.42N/AN/AN/A-329.93%-43.04%-27.41%11/6/2025 (Estimated)KYMRKymera Therapeutics-$223.86M-$3.47N/AN/AN/A-616.03%-31.60%-27.12%10/30/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.70110.72N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)SNDXSyndax Pharmaceuticals-$318.76M-$3.89N/AN/AN/A-428.48%-130.47%-56.12%11/4/2025 (Estimated)Latest SNDX, ACLX, PTGX, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ACLXArcellx-$1.00N/AN/AN/A$11.24 millionN/A11/6/2025Q3 2025PTGXProtagonist Therapeutics-$0.59N/AN/AN/A$5.41 millionN/A11/4/2025Q3 2025SNDXSyndax Pharmaceuticals-$0.73N/AN/AN/A$49.08 millionN/A10/30/2025Q3 2025KYMRKymera Therapeutics-$0.73N/AN/AN/AN/AN/A8/11/2025Q2 2025KYMRKymera Therapeutics-$0.83-$0.95-$0.12-$0.95$17.37 million$11.48 million8/7/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/6/2025Q2 2025PTGXProtagonist Therapeutics-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 million8/4/2025Q2 2025SNDXSyndax Pharmaceuticals-$1.01-$0.83+$0.18-$0.83$26.64 million$37.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A3.813.81KYMRKymera TherapeuticsN/A8.328.32PTGXProtagonist TherapeuticsN/A16.9716.97SNDXSyndax Pharmaceuticals2.064.714.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%KYMRKymera TherapeuticsN/APTGXProtagonist Therapeutics98.63%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACLXArcellx8.35%KYMRKymera Therapeutics16.01%PTGXProtagonist Therapeutics4.90%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.46 million50.83 millionOptionableKYMRKymera Therapeutics17071.50 million60.05 millionOptionablePTGXProtagonist Therapeutics12062.21 million59.16 millionOptionableSNDXSyndax Pharmaceuticals11086.14 million82.61 millionOptionableSNDX, ACLX, PTGX, and KYMR HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Illumina (ILMN)October 17 at 6:22 AM | theglobeandmail.comSyndax Pharmaceuticals (NASDAQ:SNDX) Upgraded at HC WainwrightOctober 17 at 5:51 AM | marketbeat.comWhere Syndax Pharmaceuticals Stands With AnalystsOctober 16 at 3:19 PM | benzinga.comSyndax Pharmaceuticals' (SNDX) Buy Rating Reaffirmed at HC WainwrightOctober 16 at 8:17 AM | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.9% - Here's What HappenedOctober 13, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given Sell (E+) Rating at Weiss RatingsOctober 9, 2025 | marketbeat.comEquities Analysts Issue Forecasts for SNDX FY2027 EarningsOctober 7, 2025 | americanbankingnews.comResearch Analysts Offer Predictions for SNDX FY2027 EarningsOctober 6, 2025 | marketbeat.comSyndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA DecisionOctober 4, 2025 | msn.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Buy" from AnalystsSeptember 29, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at BTIG ResearchSeptember 20, 2025 | marketbeat.comSyndax announces updated NCCN Guidelines for AMLSeptember 19, 2025 | msn.comSyndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute ...September 19, 2025 | finance.yahoo.comSyndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid LeukemiaSeptember 19, 2025 | globenewswire.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 4.8% - Time to Sell?September 17, 2025 | marketbeat.comSyndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRCSeptember 10, 2025 | seekingalpha.comSyndax resumed with Buy at Stifel on newly launched drugsSeptember 10, 2025 | msn.comStocks To Watch: Syndax Pharmaceuticals Sees Relative Strength Rating Jump To 84September 8, 2025 | msn.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comGuggenheim Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy RecommendationSeptember 4, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDX, ACLX, PTGX, and KYMR Company DescriptionsArcellx NASDAQ:ACLX$86.99 -1.86 (-2.09%) Closing price 04:00 PM EasternExtended Trading$86.94 -0.05 (-0.06%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Kymera Therapeutics NASDAQ:KYMR$59.83 -0.63 (-1.04%) Closing price 04:00 PM EasternExtended Trading$59.84 +0.01 (+0.02%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$77.50 +1.77 (+2.34%) Closing price 04:00 PM EasternExtended Trading$77.50 0.00 (0.00%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Syndax Pharmaceuticals NASDAQ:SNDX$14.30 -0.75 (-4.98%) Closing price 04:00 PM EasternExtended Trading$14.32 +0.02 (+0.15%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
